WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI ...

Luckily, 2025 has given werewolf enthusiasts one of the best stories focusing on the supernatural beasts in recent memory, and it’s a shame that many might have missed it. Earlier this year, writer ...

Citizens downgraded Werewolf Therapeutics (HOWL) to Market Perform from Outperform without a price target after the company provided updates to ...

As of Wednesday, December 17, Werewolf Therapeutics, Inc.’s HOWL share price has surged by 8.80%, which has investors questioning if this is right time to sell.

Werewolf stories have evolved and transformed throughout cinematic history in accordance with the trends and topics of each era, with their adaptability making them the perfect jumping-off point for ...

Following the official Marvel Cinematic Universe debut of fan-favorite villain Mephisto, it seems like Marvel Studios is ready to embrace more of the MCU’s supernatural side. That’s why, after more ...

Babies in Europe have been developing hypertrichosis, more commonly known as werewolf syndrome, after their parents used an anti-baldness medication. The Pharmacovigilance Center of Navarre (CFN) in ...

Emily Bernard is a Features Editor and Peer Mentor for Collider who studied History, Playwriting, and English at the University of Scranton. She’s a proud comedy nerd who loves getting into the nitty ...

Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...